当前位置:BPS Bioscience Inc.>>Immunotherapy Cell Lines>> 71273ADCP Bioassay Effector Cell FcγRIIa (H Variant)/ NFAT Luciferase Reporter Jurkat Cell Line
ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Reporter Jurkat Cells are Jurkat T cells engineered to express firefly luciferase under the control of NFAT response elements, and human FcγRIIa, H variant. This cell line was functionally validated in a ADCP (antibody-dependent cell-mediated phagocytosis) assay.
Figure 1: Illustration of the mechanism of action of ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Luciferase Reporter Jurkat Cell Line.
ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Luciferase Reporter Jurkat cells are used as effector cells. The effector cells are co-cultured in the presence of target cells and an antibody of interest. The antibody binds to the target antigen on the target cell whereas its Fc portion binds to FcγRIIa on the cell surface of the effector cell, cross-linking the effector and target cells. Engagement of FcγRIIa leads to the activation of the NFAT pathway in the effector cells. Luciferase activity is proportional to the activation of the ADCP cascade.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供,信息内容的真实性、准确性和合法性由相关企业负责,化工仪器网对此不承担任何保证责任。
温馨提示:为规避购买风险,建议您在购买产品前务必确认供应商资质及产品质量。